Ads
related to: interleukin 6 receptor blocker- Specialty Pharmacies
Work with any of our select
In-network specialty pharmacies
- HCP Resources
Helpful resources for you
and your patients with PMR
- Specialty Pharmacies
Search results
Results From The WOW.Com Content Network
Anti-interleukin-6 agents are a class of therapeutics. Interleukin 6 is a cytokine relevant to many inflammatory diseases and many cancers. [ 1 ] Hence, anti-IL6 agents have been sought.
Interleukin 6 (IL-6) is an ... IL-1 receptor antagonist (IL-1ra), and IL-10. IL-6 was serendipitously discovered as a myokine because of the observation that it ...
Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer.
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
This drug was developed by Ablynx NV to block interleukin-6 receptor. Vobarilizumab has been evaluated in patients with rheumatoid arthritis [4] as well as in lupus. [5]
Olokizumab is the first interleukin-6 (IL-6) inhibitor approved for treatment of rheumatoid arthritis which blocks directly cytokine instead of its receptor. [1] Olokizumab specifically binds to IL-6 at Site 3, blocking IL-6 ability to form hexameric complex. [2] Olokizumab was developed by R-Pharm group, and was launched in 2020. [3]
Ad
related to: interleukin 6 receptor blocker